The Australian market is experiencing a mixed phase, with recent geopolitical tensions weighing on investor sentiment despite a strong performance earlier in the week. For those looking to invest in smaller or newer companies, penny stocks—despite the name's vintage feel—can still offer surprising value. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials. Top 10 Penny Stocks In Australia Name Share Price Market Cap Financial Health Rating West African Resources (ASX:WAF) A$3.38 A$3.86B ★★★★★★ Fenix Resources (ASX:FEX) A$0.35 A$267.74M ★★★★☆☆ LaserBond (ASX:LBL) A$0.585 A$69.15M ★★★★★★ Regal Funds Management (ASX:RPL) A$2.66 A$974.64M ★★★★★★ Praemium (ASX:PPS) A$0.69 A$336.36M ★★★★★★ Ora Banda Mining (ASX:OBM) A$1.325 A$2.55B ★★★★★★ EDU Holdings (ASX:EDU) A$0.865 A$108.08M ★★★★★★ Integrated Research (ASX:IRI) A$0.30 A$54.18M ★★★★★★ CTI Logistics (ASX:CLX) A$1.88 A$147.57M ★★★★☆☆ Cogstate (ASX:CGS) A$2.40 A$410M ★★★★★★ Click here to see the full list of 391 stocks from our ASX Penny Stocks screener. Here's a peek at a few of the choices from the screener. Djerriwarrh Investments Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Djerriwarrh Investments Limited is a publicly owned investment manager with a market cap of A$767.55 million. Operations: The company generates its revenue primarily from its portfolio of investments, amounting to A$51.56 million. Market Cap: A$767.55M Djerriwarrh Investments Limited, with a market cap of A$767.55 million, has shown stable weekly volatility and high-quality earnings despite recent negative earnings growth of -19.2%. The company's net profit margins decreased from 93.6% to 74.5%, and its short-term assets (A$40.3M) do not cover short-term liabilities (A$61.8M). However, debt management remains strong with a reduced debt-to-equity ratio of 6.3% and interest payments well-covered by EBIT at 22.5x coverage. Recent strategic moves include a share buyback program for capital management, targeting up to 9.14% of issued share capital through February 2027. Unlock comprehensive insights into our analysis of Djerriwarrh Investments stock in this financial health report. Understand Djerriwarrh Investments' track record by examining our performance history report.ASX:DJW Debt to Equity History and Analysis as at Apr 2026 SiteMinder Simply Wall St Financial Health Rating: ★★★★★☆ Overview: SiteMinder Limited offers software and online licensing solutions across various regions including Asia Pacific, Europe, the Middle East, Africa, and the Americas, with a market cap of A$886.13 million. Story Continues Operations: The company generates A$251.02 million in revenue from its software and programming segment. Market Cap: A$886.13M SiteMinder Limited, with a market cap of A$886.13 million, has shown promising revenue growth, reporting A$131.1 million in sales for the half-year ended December 31, 2025. Despite being unprofitable with a net loss of A$4.78 million, the company has reduced its losses significantly from the previous year and maintains sufficient cash runway for over three years due to positive free cash flow growth. The management and board are experienced, contributing to strategic stability while remaining debt-free enhances financial flexibility. However, short-term liabilities slightly exceed short-term assets (A$60.7M vs A$69.3M). Click here to discover the nuances of SiteMinder with our detailed analytical financial health report. Evaluate SiteMinder's prospects by accessing our earnings growth report.ASX:SDR Revenue & Expenses Breakdown as at Apr 2026 XRF Scientific Simply Wall St Financial Health Rating: ★★★★★★ Overview: XRF Scientific Limited manufactures and markets precious metal products, specialized chemicals, and instruments for the scientific, analytical, construction material, and mining industries across Australia, Canada, and Europe with a market cap of A$261.76 million. Operations: The company's revenue is derived from three main segments: Consumables (A$18.07 million), Precious Metals (A$23.79 million), and Capital Equipment (A$24.60 million). Market Cap: A$261.76M XRF Scientific Limited, with a market cap of A$261.76 million, demonstrates financial stability and growth potential. The company reported half-year sales of A$31.3 million, up from the previous year, and net income increased to A$5.26 million. Its earnings are well-supported by operating cash flow, covering debt significantly. XRF's board and management team bring seasoned expertise with long tenures averaging over 12 years each. The recent establishment of an office in India aims to capitalize on the growing demand for advanced sample preparation methods in mining sectors, potentially enhancing its international revenue streams further into emerging markets like India. Navigate through the intricacies of XRF Scientific with our comprehensive balance sheet health report here. Understand XRF Scientific's earnings outlook by examining our growth report.ASX:XRF Financial Position Analysis as at Apr 2026 Next Steps Explore the 391 names from our ASX Penny Stocks screener here. Looking For Alternative Opportunities? The end of cancer? These 30 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:DJW ASX:SDR and ASX:XRF. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
ASX Penny Stocks To Consider In April 2026
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...